Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of SCT630 in rheumatoid arthritis
ChiCTR2300074783Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Health Assessment Questionnaire (HAQ). Planned start Aug 2023; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2300074783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074783.